Press release content from PR Newswire. The AP news staff was not involved in its creation.
Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March
February 11, 2021 GMT
(PRNewsfoto/Aruvant Sciences)
NEW YORK and BASEL, Switzerland, Feb. 11, 2021 /PRNewswire/ Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participation in multiple investor and scientific conferences in February and March. The company will be at the following conferences:
BIO CEO & Investor Digital Conference. Will Chou, M.D., Aruvant chief executive officer, will provide an overview of Aruvant and review data examining the company’s lead product candidate ARU-1801 as a potentially curative gene therapy for sickle cell disease. Visit https://www.bio.org/events/bio-ceo-investor-digital-conference/sessions/770479 to view the on-demand p
Share this article
Share this article
NEW YORK, Feb. 3, 2021 /PRNewswire/ Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to ARU-1801, a one-time investigational gene therapy for sickle cell disease (SCD). PRIME designation from EMA highlights the importance of ARU-1801, administered with only reduced intensity conditioning, for the treatment of individuals with severe sickle cell disease, said Will Chou, M.D., Aruvant chief executive officer. With PRIME, we will be able to work closely with EMA on the development of ARU-1801, with the goal of rapidly bringing this potential cure to SCD patients in Europe.
01/18/2021 | Press release | Distributed by Public on 01/18/2021 12:19
Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial
Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for sickle cell disease
Lonza to provide cGMP material supply of ARU-1801 for its use in a pivotal clinical study in the United States
Quote from Palani Palaniappan, Chief Technology Officer, Aruvant Sciences: We are partnering with Lonza, one of the world s leading cell and gene therapy manufacturing organizations, to help us manufacture our gene therapy, ARU-1801, a potential cure for sickle cell disease that can be given with one low dose of chemotherapy. Our internal cell therapy process expertise combined with Lonza s cell processing know-how provide the perfect combination to manufacture ARU-1801 for our pivotal study. As we advanceour gene ther
Share this article
Share this article
NEW YORK, Jan. 18, 2021 /PRNewswire/ Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop and manufacture ARU-1801 for its upcoming pivotal trial. We are partnering with Lonza, one of the world s leading cell and gene therapy manufacturing organizations, to help us manufacture our gene therapy ARU-1801, a potential cure for sickle cell disease that can be given with one low dose of chemotherapy, said Palani Palaniappan, Aruvant chief technology officer. Our internal cell therapy process expertise combined with Lonza s cell processing know-how provide the perfect combination to manufacture ARU-1801 for our pivotal study. As we advance our gene therapy through clinical trials, this partnership signifies a critical mi